EFPIA

Resolution adopted with 667 votes to 4, but research lobbies say not enough alternatives exist to set out a step-by-step plan

Industry says failure to consider new ways of assessing the value of drugs, including outcomes-based approaches and the use of real world evidence, represents a missed opportunity to promote sustainability of Europe’s healthcare systems